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About 15 years ago it was proposed that generation of the truncated protein p25 contributes
to toxicity in Alzheimer’s disease (AD). p25 is a calcium-dependent degradation product
of p35, the principal activator of cyclin-dependent kinase 5 (Cdk5). The biochemical
properties of p25 suggested that its generation would cause Cdk5 overactivation and tau
hyperphosphorylation, a prerequisite for neuroﬁbrillary tangle (NFT) formation. Whilst this
modelwas appealing as it explainedNFT formation, many laboratories could not conﬁrm the
ﬁnding of increased p25 generation in brain from AD patients. On the contrary, it emerged
that p25 levels are reduced in AD. This reduction occurs primarily in the early stages
of the disease. Further, p25 generation in the mouse hippocampus is associated with
normal memory formation and p25 overexpression enhances synaptogenesis. Therefore,
it transpires that p25 generation is a molecular memorymechanism that is impaired in early
AD. I discuss the prospect that investigation of p25-regulated proteins will shed light into
mechanisms underlying synaptic degeneration associated with memory decline in AD.
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INTRODUCTION
In the late Nineties Li-Huei Tsai’s lab published a paper proposing
that the truncated cyclin-dependent kinase 5 (Cdk5) activa-
tor p25 is speciﬁcally formed in sporadic Alzheimer’s disease
(AD; Patrick et al., 1999). This ﬁnding evoked a lot of inter-
est because it appeared to provide a missing mechanism for the
amyloid cascade hypothesis. It supplied a link between abnormal
processing of amyloid precursor protein (APP) and tau hyper-
phosphorylation, a prerequisite of neuroﬁbrillary tangle (NFT)
formation. The model (Figure 1) was as follows: Abnormal APP
processing generates amyloid peptides that oligomerize thereby
enhancing calcium signaling (Kawahara, 2010). This would result
in activation of the calcium-dependent protease calpain leading
to cleavage of p35 into p25. Both p35 and p25 are activators
of Cdk5, a major tau kinase (Angelo et al., 2006). p25 forma-
tion would overactivate Cdk5, since p25 is more stable than
p35 due to lack of an ubiquitination site (Angelo et al., 2006).
Additionally, p25 is cytosolic, in contrast to plasma membrane-
bound p35. Therefore, p25 formation can activate Cdk5 in
locations that are not close to the membrane. Consequently,
p25 formation is well positioned to cause hyperphosphoryla-
tion of “free” tau that is not associated with microtubules.
However, research over the last 15 years has shown that this
model is not correct because p25 levels are not increased in AD.
Instead it has emerged that p25 formation is a memory mech-
anism that is impaired in early AD. Here, I discuss the key
evidence leading to this conclusion and pose some outstanding
questions.
p25 EXPRESSION IS NOT INCREASED BUT REDUCED IN AD
Two years after the Patrick et al. (1999) paper another post-
mortemanalysiswas published,whichdidnot conﬁrm the claimed
upregulation of p25 expression in postmortem AD (Yoo and
Lubec, 2001). In fact this study showed a signiﬁcant down-
regulation of p25 expression in AD forebrain. This decreased
p25 expression was not simply due to neuronal loss, as it
was adjusted to the expression of a neuronal marker. How-
ever, the downregulation of p25 expression was not discussed
by the authors, possibly because p25 expression was consid-
ered toxic in line with Tsai’s lab. Instead, the key point of
discussion was that p25 upregulation was not reproducible in
postmortem AD tissue. It was realized that postmortem delay is
a variable to consider, since p25 can be formed from degrada-
tion of p35 before the tissue is frozen (Kusakawa et al., 2000).
Thus, the failure to detect p25 upregulation was attributed to
postmortem delay. However, p25 expression was downregu-
lated in the study by Yoo and Lubec (2001) indicating that the
postmortem delay was not too long. In fact, the postmortem
delay was similar to that previously reported by Patrick et al.
(1999). Two further labs also found evidence for a downregu-
lation of p25 expression in AD. In one study there was a trend
for downregulation (p = 0.06) (Tandon et al., 2003) and in the
other study p25 levels as well as p35 levels were reduced by
50% (Taniguchi et al., 2001). Recently, my lab also performed
a postmortem expression analysis (Engmann et al., 2011a). In
our work we not only compared p25 and p35 expression in
severe AD (Braak stages 5–6) as in the previously published
postmortem analyses (Patrick et al., 1999; Taniguchi et al., 2001;
Yoo and Lubec, 2001; Tseng et al., 2002; Tandon et al., 2003),
but we also examined expression in mild AD (Braak stages 1–
2). We found that p25 and p35 expression are reduced in mild
AD and there is no additional reduction in severe AD. Our
work also suggests that the sample preparation used by Tsai’s
lab may have biased their result, because they considered only
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FIGURE 1 | Models of p25 dysregulation in Alzheimer’s disease. (A)The
ﬁrst model implicating p25 in AD is shown. This model proposes that p25
expression is increased in AD. This increased expression is caused by
amyloid oligomers that increase calcium signaling enhancing cleavage of
p35 into p25. Increased p25 expression leads to an overactivation and
mislocalization of Cdk5, which results in tau hyperphosphorylation, which is
a prerequisite for neuroﬁbrillary tangle formation and neurodegeneration.
(B) Revised model of p25 dysregulation in AD. This model proposes that
p25 expression is not increased but reduced in AD. This decreased
expression is caused by amyloid oligomers that decrease NMDA
receptor-dependent calcium signaling at the synapse (due to internalization
and desensitization of NMDA receptors) impairing cleavage of p35 into p25.
Decreased p25 expression reduces synthesis of particular synaptic
proteins, which affects synaptogenesis, late LTP and memory formation.
protein that was remaining after a long highspeed centrifuga-
tion step which biases p25/p35 (Engmann et al., 2011a). Taken
together, various postmortem analyses have revealed that p25
expression is not increased in AD as widely thought; instead
p25 expression is actually reduced. Reduced p25 in AD is in
agreement with amyloid-induced synaptic toxicity, since amyloid
oligomers eventually decrease calcium signaling at the synapse due
to internalization and desensitization of N-methyl-D-aspartate
(NMDA) receptors (Palop and Mucke, 2010; Paula-Lima et al.,
2013).
MOUSE MODELS OF p25 EXPRESSION
Motivated by the Patrick et al. (1999) paper, various transgenic
mouse models were generated expressing high levels of p25, in
most cases during embryonic development, which confounds the
analysis as Cdk5 has developmental functions (see, Giese et al.,
2005). High-level p25 expressing mouse models suffer from neu-
rodegeneration (e.g., Fischer et al., 2005). Thus, it is clear that
overexpression of p25 can be neurotoxic. This is likely due to
pathological processing of key disease proteins such as tau and
APP, which may be an artifact of overexpression. However, this
model of neurotoxicity is not relevant to AD, since p25 levels are
not increased but reduced in AD.
p25 GENERATION DURING SPATIAL MEMORY FORMATION
How can p25 expression be reduced in AD? A reduction in
p25 expression indicates that p25 formation occurs under nor-
mal physiological conditions, and that such physiological p25
generation is impaired in AD. In agreement with this, spa-
tial memory formation is associated with p25 generation in the
mousehippocampus (Engmannet al.,2011a). Importantly, behav-
ioral controls did not show any p25 generation in the mouse
hippocampus in the absence of memory formation.
The importance of p25 generation for spatial memory has been
tested in various mutant mouse lines. First, mutant mice express-
ing low levels of p25 under control of the αCaMKII promoter
which is active in postnatal forebrain, show improved spatial
memory formation (Angelo et al., 2003; Ris et al., 2005). Sec-
ond, short-lasting overexpression of p25 under inducible control
of the αCaMKII promoter also enhances spatial memory forma-
tion (Fischer et al., 2005). Third, heterozygous p35 knockoutmice,
which are thought to generate less p25 than wild-type mice, have
impaired spatial reversal learning (Engmann et al., 2011b). Taken
together, these studies suggest that p25 generation is important
for spatial memory formation. In future, it will be important to
conﬁrm this hypothesis with p35 knock-in mutants that lack the
calpain cleavage site, precluding p25 generation.
HOW DOES p25 GENERATION IMPROVE MEMORY
FORMATION?
Overexpression of physiological levels of p25, or transient expres-
sion of high levels of p25 enhance spatial memory formation
(Angelo et al., 2003; Fischer et al., 2005; Ris et al., 2005). In these
models p25 overexpression increases synapse density (Fischer
et al., 2005; Engmann et al., 2011a) and the late phase of hip-
pocampal CA1 LTP (Ris et al., 2005). These ﬁndings suggest that
p25 generation leads to increased protein synthesis that is required
for late LTP and synaptogenesis. This idea was tested by analysis of
the synaptic proteome of p25 mutants in comparison to control
littermates (Engmann et al., 2010, 2011a). It was found that p25
overexpression increases the expression of fewer than 20 synaptic
proteins out of approximately 1000 proteins analyzed. Thus, p25
generation during spatial memory formation may increase syn-
thesis of a few synaptic proteins that may induce synaptogenesis
and contribute to the late phase of LTP. It is conceivable that p25
acts as a signal from synapse to nucleus (see, O’Hare et al., 2005)
to stimulate expression of genes encoding synaptic proteins. Alter-
natively, p25 may induce translation of mRNAs that are located at
synapses, although there is currently no evidence that Cdk5 reg-
ulates local protein synthesis. In any case, p25 generation seems
to be implicated in speciﬁc protein synthesis that is required for
synaptogenesis and long-lasting LTP.
THE IMPACT OF p25 DOWNREGULATION IN AD
In AD synapse loss, which precedes neuronal loss, correlates best
with impaired memory formation (Arendt, 2009; Serrano-Pozo
et al., 2012). Thus, synaptic dysfunction is fundamental for the
early stages of AD (see also, Selkoe, 2002). The downregulation of
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p25 expression in AD is expected to contribute to synaptic dys-
function in early AD, because (i) p25 generation is linked with
synaptogenesis and LTP (Fischer et al., 2005; Ris et al., 2005; Eng-
mannet al.,2011a,b), (ii) downregulationof p25 generationoccurs
in the early stages of AD (Engmann et al., 2011a), and (iii) p25
generation is associated with memory formation. Since p25 gen-
eration regulates the expression of particular synaptic proteins
(Engmann et al., 2011a), p25-regulated synaptic proteins may be
reduced in their expression in early AD and this may lead to
synaptic degeneration. This idea was tested in the case of optic
atrophy 1 (OPA1) and septin 7, both being p25-regulated pro-
teins (Engmann et al., 2011a). OPA1 is a mitochondrial protein
involved in mitochondrial fusion as well as spinogenesis (Cipo-
lat et al., 2004; Wang et al., 2009). Septin 7 is a GTP-binding
protein that is localized to the spine neck, where it controls
spinogenesis and morphology of the spines (Tada et al., 2007;
Xie et al., 2007). Whilst the expression of septin 7 does not
appear to be altered in postmortem AD brain, OPA1 expression is
reduced in the hippocampus in early AD (Engmann et al., 2011a).
This suggests that dysregulation of p25-regulated synaptic pro-
teins contributes to synaptic dysfunction in early AD. In future,
the functional impact of these dysregulations will need to be
determined.
Cdk5 and glycogen synthase 3 (GSK-3) are thought to be the
main tau kinases (Engmann and Giese, 2009). In AD reduction
of p25 and p35 expression in hippocampus correlates with tau
hyperphosphorylation (Engmann et al., 2011a). Reduced p25 and
p35 expression should result in decreased Cdk5 activity in AD and
consequently Cdk5 may not be the critical tau kinase. Instead,
reduced p25 and p35 expression may result in a loss of inhibi-
tion of GSK-3 which should lead to tau hyperphosphorylation. In
agreement with this idea, inhibitory crosstalk between Cdk5 and
GSK-3 was demonstrated (Plattner et al., 2006; Wen et al., 2008).
Thus, reduced p25 expression is expected to lead to an overactiva-
tion of GSK-3 activity that causes tau hyperphosphorylation. This
scenario would be consistent with other evidences that GSK-3may
be a critical tau kinase in AD (Hooper et al., 2008).
CONCLUDING REMARKS
In recent years it has emerged that p25 is not an exclusively toxic
molecule. Spatial memory formation leads to p25 generation in
the hippocampus, where p25 can stimulate synthesis of synaptic
proteins followed by synaptogenesis and synaptic strengthening.
In the early stages of AD hippocampal p25 expression is reduced.
Taken together, this suggests that p25 generation is a memory
mechanism that is affected in early AD (Figure 1). Impaired p25
generation in AD is expected to contribute to synaptic degenera-
tion in the disease. However, more studies are needed to establish
the precise synaptic function of p25. For example, p25 genera-
tion could be a signal from synapse to nucleus to stimulate gene
expression needed for long-lasting synaptic plasticity. Recent evi-
dence also shows that the expression of p25-regulated synaptic
proteins is downregulated in early AD hippocampus. Analysis
of these synaptic downregulations promises to give insight into
the mechanisms of early synaptic degeneration in AD. So far,
it has emerged that p25-regulated proteins are downregulated
at the pre- and post-synaptic side, suggesting that degeneration
occurs equally at both sides of the synapse. This is consistent
with the ﬁnding that oligomeric amyloid peptide binds to pre-
and post-synapses and has the potential to induce dysfunction
on both sides of the synaptic cleft (Kofﬁe et al., 2012). It is
hoped that in future a mechanistic understanding of synaptic
degeneration in AD will lead to the development of pharmaco-
logical approaches to contain this devastating disease in its early
stages.
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